U.S. teenagers should not be included in any HIV vaccine research because the risks outweigh any benefits, a Food and Drug Administration panel has determined. While including adolescents in countries where HIV is more prevalent is justified because of the heightened infection risks facing those teenagers, the low HIV prevalence rate among U.S. teens does not warrant including them in clinical trials, the FDA says.
